Lisa Decker
About Lisa Decker
Lisa Decker serves as the Chief Business Officer at IGM Biosciences, Inc. and has extensive experience in business development and operations within the biotechnology sector.
Current Role at IGM Biosciences
Lisa Decker serves as the Chief Business Officer at IGM Biosciences, Inc. since 2021. In this role, she is responsible for overseeing business operations and strategic initiatives within the organization. IGM Biosciences is located in Mountain View, California, and focuses on developing innovative immunotherapies for cancer treatment. Decker's leadership contributes to the company's mission of advancing therapeutic solutions in the biotechnology sector.
Experience at Chimerix, Inc.
In addition to her role at IGM Biosciences, Lisa Decker has been a member of the Board of Directors at Chimerix, Inc. since 2023. This position allows her to provide strategic guidance and oversight to the organization, which specializes in developing antiviral therapeutics. Her involvement with Chimerix reflects her commitment to advancing healthcare solutions.
Previous Positions at Nektar Therapeutics
Lisa Decker held multiple roles at Nektar Therapeutics from 2008 to 2019. She started as Senior Director of Alliance Management, then progressed to Executive Director of Business Strategy and Operations, and later served as Vice President and Executive Director of Business Development. These positions involved managing partnerships and driving business strategies that supported the company's growth in the biopharmaceutical industry.
Educational Background in Immunology
Lisa Decker earned her Ph.D. in Immunology from Tufts University School of Medicine, where she studied from 1992 to 1998. She also holds a Bachelor of Arts in Biology from the College of the Holy Cross, obtained from 1986 to 1990. Her educational background provides a strong foundation for her career in the biotechnology and pharmaceutical sectors.
Career at Atreca, Inc.
Before joining IGM Biosciences, Lisa Decker served as Chief Business Officer at Atreca, Inc. from 2019 to 2021. In this role, she was responsible for leading business development efforts and strategic planning. Atreca focuses on developing novel immunotherapies for cancer treatment, aligning with Decker's expertise in the field.